This site is intended for Healthcare professionals only.
×

Lupin launches NaMuscla in Germany and UK for treating Myotonic Disorders


Lupin launches NaMuscla in Germany and UK for treating Myotonic Disorders

Lupin has ongoing partnering discussions for the commercialization of NaMuscla in European territories outside of Germany and the UK.

Mumbai: As stated earlier by drug major Lupin that it is preparing for the launch of NaMuscla, which would occur in the initial markets of Germany and the UK in the first quarter of 2019, the firm has recently announced that NaMuscla(mexiletine) has been launched in Germany and the United Kingdom (UK).

NaMuscla is approved across the European Union (EU) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. These disorders are a group of rare, inherited neuromuscular conditions in which myotonia, the inability to relax muscles following voluntary contraction, is the most prominent clinical symptom.

NaMuscla reduces myotonia symptoms in adult patients, resulting in a significant improvement in patient quality-of-life and other functional outcomes.

Also Read: Lupin gets European Commission nod for NaMuscla

The launch of NaMuscla in Germany and the UK follows the European Commission’s approval of the product on 18 December 2018. NaMuscla, designated an Orphan Drug by the European Medicines Agency (EMA), is the first treatment to be licensed across the EU for the symptomatic treatment of myotonia in adults with NDM disorders. The product will be commercialized in Germany by Hormosan Pharma GmbH, a full subsidiary of Lupin Ltd., and in the UK by Lupin Healthcare (UK) Ltd.

“We are delighted to be able to provide patient and market access to NaMuscla in Germany and the UK,” said Thierry Volle, President EMEA, Lupin. “NaMuscla is the first licensed therapy for myotonia across the EU and offers an effective treatment option for patients living with this life-altering symptom. We look forward to additional launches for patients in other EU territories through 2019 and 2020.”

Lupin has ongoing partnering discussions for the commercialization of NaMuscla in European territories outside of Germany and the UK.

Lupin is a Mumbai based pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.



Source: self
0 comment(s) on Lupin launches NaMuscla in Germany and UK for treating Myotonic Disorders

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted